BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24333426)

  • 1. HER4 selectively coregulates estrogen stimulated genes associated with breast tumor cell proliferation.
    Han W; Jones FE
    Biochem Biophys Res Commun; 2014 Jan; 443(2):458-63. PubMed ID: 24333426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium.
    Rokicki J; Das PM; Giltnane JM; Wansbury O; Rimm DL; Howard BA; Jones FE
    Mol Cancer; 2010 Jun; 9():150. PubMed ID: 20550710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells.
    Zhu Y; Sullivan LL; Nair SS; Williams CC; Pandey AK; Marrero L; Vadlamudi RK; Jones FE
    Cancer Res; 2006 Aug; 66(16):7991-8. PubMed ID: 16912174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrinsic HER4/4ICD transcriptional activation domains are required for STAT5A activated gene expression.
    Han W; Sfondouris ME; Semmes EC; Meyer AM; Jones FE
    Gene; 2016 Oct; 592(1):221-226. PubMed ID: 27502417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct coupling of the HER4 intracellular domain (4ICD) and STAT5A signaling is required to induce mammary epithelial cell differentiation.
    Han W; Sfondouris ME; Jones FE
    Biochem Biophys Rep; 2016 Sep; 7():323-327. PubMed ID: 28955922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.
    Jones FE
    J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):247-58. PubMed ID: 18473151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients.
    Thor AD; Edgerton SM; Jones FE
    Am J Pathol; 2009 Nov; 175(5):1802-9. PubMed ID: 19808643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
    Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
    Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.
    Naresh A; Thor AD; Edgerton SM; Torkko KC; Kumar R; Jones FE
    Cancer Res; 2008 Aug; 68(15):6387-95. PubMed ID: 18676864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity.
    Karmakar S; Foster EA; Smith CL
    Endocrinology; 2009 Apr; 150(4):1588-96. PubMed ID: 19095746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.
    Naresh A; Long W; Vidal GA; Wimley WC; Marrero L; Sartor CI; Tovey S; Cooke TG; Bartlett JM; Jones FE
    Cancer Res; 2006 Jun; 66(12):6412-20. PubMed ID: 16778220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer.
    Fujiwara S; Hung M; Yamamoto-Ibusuk CM; Yamamoto Y; Yamamoto S; Tomiguchi M; Takeshita T; Hayashi M; Sueta A; Iwase H
    Oncotarget; 2014 Jun; 5(11):3919-30. PubMed ID: 25003574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.
    Zou Y; Tsai WB; Cheng CJ; Hsu C; Chung YM; Li PC; Lin SH; Hu MC
    Breast Cancer Res; 2008; 10(1):R21. PubMed ID: 18312651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation.
    Stender JD; Frasor J; Komm B; Chang KC; Kraus WL; Katzenellenbogen BS
    Mol Endocrinol; 2007 Sep; 21(9):2112-23. PubMed ID: 17550982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of steroid receptor coactivator-2 modulates estrogen-responsive genes and stimulates proliferation of mcf-7 breast cancer cells.
    Fenne IS; Helland T; Flågeng MH; Dankel SN; Mellgren G; Sagen JV
    PLoS One; 2013; 8(7):e70096. PubMed ID: 23936147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
    Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
    Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
    Zhang X; Diaz MR; Yee D
    Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2.
    Tan S; Ding K; Li R; Zhang W; Li G; Kong X; Qian P; Lobie PE; Zhu T
    Breast Cancer Res; 2014 Apr; 16(2):R40. PubMed ID: 24735615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen.
    Göthlin Eremo A; Tina E; Wegman P; Stål O; Fransén K; Fornander T; Wingren S
    Int J Oncol; 2015 Oct; 47(4):1311-20. PubMed ID: 26238412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.